Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · June 13, 2022

Trastuzumab Deruxtecan in Patients With CNS Involvement From HER2+ Breast Cancer



Additional Info

Disclosure statements are available on the authors' profiles:

Trastuzumab Deruxtecan in Patients with Central Nervous System Involvement from HER2-Positive Breast Cancer: The DEBBRAH Trial
Neuro-oncology 2022 May 26;[EPub Ahead of Print], JM Pérez-García, MV Batista, P Cortez, M Ruiz-Borrego, JM Cejalvo, J de la Haba-Rodriguez, L Garrigós, F Racca, S Servitja, S Blanch, M Gion, M Nave, M Fernández-Abad, A Martinez-Bueno, A Llombart-Cussac, M Sampayo-Cordero, A Malfettone, J Cortés, S Braga

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Brain Cancer Center of Excellence

Visit our Brain Cancer Center of Excellence for additional, in-depth coverage.

Further Reading